Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07084818

Enabling Self-Care for Pessary Users in Rural Setting

This study is to see if a using new collapsible pessary (Reia pessary) for treatment of pelvic organ prolapse will allow patients to care for their prolapse on their own, rather than having to come to be seen by a provider in the office regularly (2-4 times per year) to manage the pessary. Enrollment in the study will be offered to current patients who have regular office visits to care for their pessary.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

About this study

This is a prospective interventional trial for patients with at least stage 2 pelvic organ prolapse (POP), who are currently managing their POP with office-based care using a pessary. The study will be conducted at two institutions, Dartmouth-Hitchcock and Pennsylvania State University. The intervention will be to convert willing patients from office-based care to self-care, using a new, collapsible (Reia) pessary in patients. The primary outcome will be a visual analog score (VAS) regarding their current satisfaction with their treatment and management of POP. Secondary outcomes will include questionnaires on impact, travel for care and self-care. The comparison group will be patients who decline to try the new pessary but agree to questionnaires regarding their current office-based care for pessary management.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women currently using office-based pessary management of at least stage 2 POP will be recruited:
  • English-speaking natal females 18 years or older
  • Stage II-IV POP desiring continued pessary management.
  • Primary indication for pessary management is treatment of POP

Exclusion criteria

  • Primary indication for pessary is for management of stress urinary incontinence
  • Vesicovaginal fistula or rectovaginal fistula
  • Vaginal, rectal or bladder malignancy
  • Genitourinary infection requiring treatment*
  • Ongoing treatment for vaginal infections (e.g., chronic bacterial vaginosis)*
  • Inflammatory bowel disease (Crohn's or ulcerative colitis)
  • Pelvic or anorectal chronic pain
  • Pelvic floor surgery within the past 6 months or planning to undergo pelvic floor surgery
  • Congenital malformation of the bladder, rectum or vagina
  • The following special populations will be excluded:

Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant women (or planning pregnancy in the next 6 months) (women of childbearing age will be verbally queried and offered pregnancy testing if uncertain) Prisoners

*Patients with acute vaginal infections will be eligible for enrollment 2 weeks after completing treatment and have resolution of symptoms

Treatment and study plan

Reia System pessary self-care management

Device

The Reia-System pessary is an FDA-cleared device to manage pelvic organ prolapse which is collapsible and intended to be more easily removed, with less discomfort.

Other names: collapsible pessary

Standard pessary office-based management

Device

These subjects will continue with the current pessary they are using to manage their prolapse, with office-based care.

Other names: Ring pessary, Gellhorn pessary, donut pessary, cube pessary

Primary outcomes

  1. Visual Analogue Score (VAS): satisfaction of prolapse management.

    Time frame: Baseline, 3 months, 6 months

    Patient reported Visual Analogue Score for (0-100mm) for satisfaction of prolapse management.

Secondary outcomes

  1. modified Patient Experience with Treatment and Self-Management (mPETS) Questionnaire

    Time frame: Baseline, 6 months

    modified Patient Experience with Treatment and Self-Management Questionnaire. This is a 41-item questionnaire that is validated for patient experience with treatment and self-management of diseases as a measure of treatment burden. The questionnaire has been shortened from the original 48-item questionnaire in the original study by Eton et al and it has been slightly modified to address how prolapse and pessary care impacts treatment burden. Minimum value = 41, Maximum value = 205. Higher PETS scores are associated with greater treatment burden, with more distress, less satisfaction with medications, lower self-efficacy, worse physical and mental health, and lower convenience of healthcare.

  2. Patient Experience with Pessary Treatment and Self-Management (PEPS) Questionnaire

    Time frame: Baseline, 6 months

    Patient Experience with Pessary Treatment and Self-Management Questionnaire. This is a non-validated 11-item questionnaire that is focused on factual information regarding patient's care of their prolapse, including how long they have used a pessary, if they have cared for it themselves, how far they travel for care, how often they have their pessary checked by a practitioner. There are a few individual scaled questions with Likert responses, regarding discomfort of pessary removal and reinsertion (0-4, with the highest score being the worst outcome, "very uncomfortable"); bother of care for the pessary (0-5, the highest score being the worst outcome, "very bothersome"); interest in taking care of the pessary (0-5, the highest score being the worst outcome, "not interested at all". There is one visual analogue score (minimum 0, maximum 10) on how bothersome it is to have to travel for office care several times per year.

  3. Pelvic Floor Impact Questionnaire - 7 (PFIQ-7)

    Time frame: Baseline, 6 months

    Pelvic Floor Impact Questionnaire - 7. This is a validated 7-item questionnaire that assesses treatment on pelvic floor impact for urinary symptoms, prolapse symptoms and colorectal symptoms. Each of the seven questions for each symptom category (bladder, prolapse, rectal) has a scale of 0-3, with higher scores being worse. The total PFIQ-7 score range is 0-300, with the higher score being worse. It has been used in many studies on prolapse, including preliminary studies on the Reia pessary.

  4. Pessary Sexual Questionnaire

    Time frame: Baseline, 6 months

    This is a non-validated 8-item questionnaire on sexual activity for subjects and whether the pessary impacts ability to be sexually active. Most questions are informational yes/no responses. The last question is a Likert scale [0-3] regarding how much the current pessary interferes with being able to be sexually active, with 3 being worse, "interferes a lot".

  5. Patient Global Impression of Improvement (PGI-I)

    Time frame: 3 months, 6 months

    Patient Global Impression of Improvement: Validated one-item questionnaire (Likert scale, 1-7); The highest score is a worse outcome.

  6. Patient Global Impression of Severity (PGI-S)

    Time frame: Baseline, 3 months, 6 months

    Patient Global Impression of Severity: Validated one-item assessment of severity of prolapse condition (Likert scale, 1-4). The highest score is a worse outcome.

  7. Patient Global Symptoms Rating Scale (PGSC)

    Time frame: Baseline, 3 months, 6 months

    Patient Global Symptoms Rating Scale (PGSC): Non-validated one-item questionnaire of treatment and adequacy of control of symptoms (Likert scale, 1-5); The highest score is a better outcome.

  8. Number of subjects with at least one adverse event

    Time frame: 0-6 months

    Adverse events will be collected, including discharge, bleeding, pain during the course of the study in both the intervention group and the continued office-based care group. There is not a maximum number of adverse events but a The highest number is a worse outcome.

  9. Log of pessary self-care events

    Time frame: 0-6 months

    Patients who decide to learn self-management of their pessary will record the number of times they remove and reinsert the pessary.

Sponsors and collaborators

Lead sponsor

Dartmouth-Hitchcock Medical Center

Other

Collaborators

  • Penn State University

Registry information

Acronym: ESCAPE

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 25, 2025
Registry last updated
Nov 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.